Business
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
– Recent data demonstrating reductions in seizure frequency and improvements in cognition and behavior support the potential for STK-001 as a
About this update from Stoke Therapeutics, Inc.
[{"type":"text","content":"\n– Recent data demonstrating reductions in seizure frequency and improvements in cognition and behavior support the potential for STK-001 as a disease-modifying potential medicine for the treatment of Dravet syndrome –\n\n\n– Company plans to meet with regulatory agencies to discuss registrational study design for STK-001; Update anticipated in the second half of 2024 –\n\n\n– As of March 31, 2024, Company had $178.6 million in cash and cash equivalents –\n\n\n– In April, Company strengthened its cash position with $120.3 million in net proceeds from public follow-on offering –\n\n\n BEDFORD, Mass.--(BUSINESS WIRE)--\nStoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2024 and provided business updates including those related to STK-001, the Company’s proprietary antisense oligonucleotide (ASO) which is in development by Stoke as the first potential medicine to address the genetic cause of Dravet syndrome.\n\n\n“In the first quarter of 2024, Stoke took a major step forward in our effort to advance the first potential disease-modifying medicine for patients with Dravet syndrome,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. “Our recent data that showed substantial and durable reductions in seizure frequency and clinically meaningful improvements across multiple measures of cognition and behavior on top of the best available anti-seizure medicines support our belief that we are addressing the root cause of Dravet syndrome. We are working with a sense of urgency to meet with regulatory agencies to discuss our plans for a randomized, controlled registrational study for STK-001 and look forward to providing an update in the second half of 2024.”\n\n\nRecent Program Highlights and Upcoming Milestones\n\n\n\nIn March, the Company shared positive new data from 81 patients treated in the Phase 1/2a and OLE studies of STK-001 in children and adolescents with Dravet syndrome. These data showed substantial and durable reductions in seizures and clinically meaningful improvements in multiple measures of cognition and behavior that support the potential for disease modification. Single and multiple doses of STK-001 up t...